Matthew Brams

Summary

Publications

  1. doi request reprint A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: late-day symptom control
    Matthew Brams
    Menninger Department of Psychiatry, Baylor College of Medicine, Houston, TX 77007, USA
    J Clin Psychopharmacol 32:637-44. 2012
  2. doi request reprint Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design
    Matthew Brams
    Bayou City Research, Houston, TX 77007, USA
    J Clin Psychiatry 73:977-83. 2012
  3. pmc Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design
    Timothy Wigal
    Department of Pediatrics, University of California, Irvine, Child Development Center, Irvine, CA, USA
    Behav Brain Funct 6:34. 2010
  4. doi request reprint Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD
    Matthew Brams
    Bayou City Research, Houston, TX 77007, USA
    Postgrad Med 123:99-108. 2011
  5. ncbi request reprint A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect
    Matthew Brams
    Baylor College of Medicine, Houston, Texas 77019, USA
    CNS Drugs 22:693-704. 2008
  6. doi request reprint Duration of effect of oral long-acting stimulant medications for ADHD throughout the day
    Matthew Brams
    Baylor College of Medicine, Houston, TX, USA
    Curr Med Res Opin 26:1809-25. 2010
  7. doi request reprint A physician's guide to helping patients with ADHD find success in the workplace
    Alice R Mao
    Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX 77007, USA
    Postgrad Med 123:60-70. 2011
  8. ncbi request reprint Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder
    Richard Weisler
    Department of Psychiatry, University of North Carolina, Chapel Hill, USA
    CNS Spectr 14:573-85. 2009
  9. doi request reprint Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults
    Thomas E Brown
    Yale Clinic for Attention and Related Disorders, Yale University School of Medicine, 1188 Whitney Ave, PO Box 6694, Hamden, New Haven, CT 06517, USA
    Postgrad Med 122:7-17. 2010
  10. doi request reprint ADHD in adults: current treatment trends with consideration of abuse potential of medications
    Alice R Mao
    Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, 500 Westcott Drive, Houston, TX 77007, USA
    J Psychiatr Pract 17:241-50. 2011

Detail Information

Publications11

  1. doi request reprint A randomized, double-blind study of 30 versus 20 mg dexmethylphenidate extended-release in children with attention-deficit/hyperactivity disorder: late-day symptom control
    Matthew Brams
    Menninger Department of Psychiatry, Baylor College of Medicine, Houston, TX 77007, USA
    J Clin Psychopharmacol 32:637-44. 2012
    ..Tolerability was comparable between doses. Dexmethylphenidate extended-release 30-mg dose may provide further benefit to patients who do not maintain optimal symptom control later in the day with D-MPH-ER 20 mg...
  2. doi request reprint Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design
    Matthew Brams
    Bayou City Research, Houston, TX 77007, USA
    J Clin Psychiatry 73:977-83. 2012
    ..To evaluate lisdexamfetamine dimesylate maintenance of efficacy in adults with attention-deficit/hyperactivity disorder (ADHD)...
  3. pmc Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design
    Timothy Wigal
    Department of Pediatrics, University of California, Irvine, Child Development Center, Irvine, CA, USA
    Behav Brain Funct 6:34. 2010
    ..Duration of efficacy and safety of lisdexamfetamine dimesylate (LDX) was assessed in adults (18-55 years) with attention-deficit/hyperactivity disorder (ADHD) using the simulated adult workplace environment...
  4. doi request reprint Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD
    Matthew Brams
    Bayou City Research, Houston, TX 77007, USA
    Postgrad Med 123:99-108. 2011
    ..To assess improvements in quality of life measurements during the open-label portion of a trial examining duration of efficacy of lisdexamfetamine dimesylate in a simulated adult workplace environment...
  5. ncbi request reprint A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect
    Matthew Brams
    Baylor College of Medicine, Houston, Texas 77019, USA
    CNS Drugs 22:693-704. 2008
    ..5 hours post-dose on the Swanson, Kotkin, Agler, M-Flynn and Pelham (SKAMP) rating scale...
  6. doi request reprint Duration of effect of oral long-acting stimulant medications for ADHD throughout the day
    Matthew Brams
    Baylor College of Medicine, Houston, TX, USA
    Curr Med Res Opin 26:1809-25. 2010
    ..To examine duration of efficacy in long-acting stimulant treatment of attention-deficit/hyperactivity disorder (ADHD) in clinical trials using analog classroom protocols...
  7. doi request reprint A physician's guide to helping patients with ADHD find success in the workplace
    Alice R Mao
    Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX 77007, USA
    Postgrad Med 123:60-70. 2011
    ..With early and successful intervention, adults with ADHD may be able to become more aware of the impact of ADHD on work performance and achieve successful occupational experiences...
  8. ncbi request reprint Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder
    Richard Weisler
    Department of Psychiatry, University of North Carolina, Chapel Hill, USA
    CNS Spectr 14:573-85. 2009
    ..To evaluate the long-term safety and effectiveness of lisdexamfetamine dimesylate (LDX) in the treatment of adults with attention-deficit/hyperactivity disorder (ADHD)...
  9. doi request reprint Open-label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention-deficit/hyperactivity disorder in adults
    Thomas E Brown
    Yale Clinic for Attention and Related Disorders, Yale University School of Medicine, 1188 Whitney Ave, PO Box 6694, Hamden, New Haven, CT 06517, USA
    Postgrad Med 122:7-17. 2010
    ..Poor self-regulation and control of emotional behaviors frequently are seen in patients with ADHD. This study assessed EF behaviors in adults with ADHD at baseline and after 4 weeks of treatment with lisdexamfetamine dimesylate (LDX)...
  10. doi request reprint ADHD in adults: current treatment trends with consideration of abuse potential of medications
    Alice R Mao
    Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, 500 Westcott Drive, Houston, TX 77007, USA
    J Psychiatr Pract 17:241-50. 2011
    ....
  11. doi request reprint Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder
    Matthew Brams
    Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX 77007, USA
    Postgrad Med 120:69-88. 2008
    ..Some formulations release a comparatively larger bolus after dosing and can result in different onset and duration of efficacy...